# Kevin Marks

> Kevin Marks is the co-founder, President and CEO of Delphia Therapeutics, a Cambridge, Massachusetts biotech pioneering 'activation lethality' - a contrarian approach that kills cancer by overdriving the very oncogenes other drugs try to switch off. A two-decade cancer drug hunter who helped advance three FDA-approved medicines at Agios and led oncology drug discovery at Novartis, Marks built Delphia as an entrepreneur-in-residence at GV (Google Ventures), launching it in 2024 with a $67 million Series A.

- **Role:** President & CEO at Delphia Therapeutics
- **Organizations:** Delphia Therapeutics, GV (Google Ventures), Novartis Institutes for BioMedical Research, Agios Pharmaceuticals, Makoto Life Sciences, Curis
- **Nationality:** American
- **Education:** B.A. in Cell Biology, Cornell University, Ph.D. in Molecular Pharmacology / Chemical & Systems Biology, Stanford University
- **Known for:** Contributed to three FDA-approved cancer and rare-disease medicines at Agios (IDHIFA, TIBSOVO, PYRUKYND), Co-founded Delphia Therapeutics and pioneered the field of 'activation lethality', Raised a $67 million Series A led by GV, Nextech Invest, Polaris Innovation Fund and Alexandria Venture Investments

## Career timeline

- **2010** — Joined Agios Pharmaceuticals as an early employee, eventually becoming VP and Head of Biology
- **2020** — Became Head of Oncology Drug Discovery at Novartis Institutes for BioMedical Research
- **2022** — Joined GV as an entrepreneur-in-residence and founded Delphia Therapeutics
- **2024** — Launched Delphia Therapeutics with a $67M Series A as co-founder, President and CEO
- **2025** — Named to BioSpace's NextGen Class of 2025

## Achievements

- Contributed to three FDA-approved cancer and rare-disease medicines at Agios (IDHIFA, TIBSOVO, PYRUKYND)
- Co-founded Delphia Therapeutics and pioneered the field of 'activation lethality'
- Raised a $67 million Series A led by GV, Nextech Invest, Polaris Innovation Fund and Alexandria Venture Investments
- Led oncology drug discovery teams at Novartis
- Named to BioSpace NextGen Class of 2025

## Latest updates

- **2024-05** — Launched Delphia Therapeutics with a $67M Series A to pioneer activation lethality
- **2025-01** — Featured in BioSpace's NextGen Class of 2025 podcast, recorded at the J.P. Morgan Healthcare Conference

## Links

- Website: https://delphiatx.com
- LinkedIn: http://www.linkedin.com/in/kevin-marks-5aa0724
- Twitter/X: https://twitter.com/marksy11

---

Profile page: https://yespress.io/kevin-marks
Published by YesPress — https://yespress.io
Last updated: 2026-06-11